King's Wealth News | Co-Health Pharmaceuticals (02171) announced that the Food and Drug Administration of the United States (FDA) has lifted the clinical trial suspension in the United States for zevor-cel injection (zevor-cel, CT053, a self-targeting CAR-T cell product for BCMA), satri-cel injection (satri-cel, CT041, a self-targeting CAR-T cell product for Claudin18.2), and CT071 (a self-targeting CAR-T cell product for GPRC5D). The suspension of the clinical trials is related to the findings announced after the FDA's inspection of the company's clinical production base in Durham, North Carolina in December 2023.
【港股通】科济药业(02171)FDA解除对泽沃基奥仑赛注射液和CT071等的美国临床研究暂停
[Hong Kong Stock Connect] KPC Pharmaceuticals (02171) FDA lifts the US clinical trial suspension of Zovokioran injection and CT071.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated